A recent clinical trial, outlined in the New England Journal of Medicine, compared the effectiveness of AstraZeneca’s drug Ticagrelor (trade name Brilinta) and aspirin. Brilinta is used for the prevention of thrombotic events, like strokes or heart attacks.
The clinical trial, nicknamed Socrates, was conducted between January, 2014 and October, 2015 throughout 33 countries and involved over 13,000 patients. Patients were either given Brilinta twice daily, or aspirin once a day, to treat acute stroke or Transient Ischemic Attack.
Ultimately, the trial found no statistically significant difference between taking Brilinta or aspirin in preventing strokes, stating “… our trial involving patients with acute ischemic stroke or transient ischemic attack, ticagrelor was not found to be superior to aspirin in reducing the risk of the composite end point of stroke, myocardial infarction, or death.”
AstraZeneca’s Chief Executive Officer Pascal Soriot considers Brilinta as critical component of the company’s success to fend off a takeover attempt by Pfizer Inc and were forecasting for Brilinta sales of $3.5 billion in 2023.
To read the entire article in the New England Journal of Medicine site, please click here.
Maglio, Christopher & Toale, P.A. helps people who’ve been hurt by dangerous medications and defective medical devices. You can contact us by filling out the form on the bottom of this page or call us at 1-888-952-5242 to speak with someone immediately about your situation.